News

Zurich - Zurich-based Smart Blood Analytics Swiss has become the first company to obtain EU-MDR certification for software that uses artificial intelligence to interpret blood test results. This will enable faster and more accurate clinical decisions.

Pfäffikon - Spiden has made significant progress in the area of non-invasive glucose measurements. The company hopes to develop a wearable device on the basis of its new technical solution. Alongside the scientific success, Spiden has also secured financing of 15 million US dollars.

Zug - Air France KLM Martinair Cargo, the airfreight business of the Air France KLM Group, has opted to deploy the SkyMind technology platform developed by SkyCell for the management of its containers and pallets. In this context, the Internet of Things (IoT) facilitates end-to-end tracking of the container assets.

Zug/Wake Forest - SHL Medical has acquired the firm Superior Tooling from the USA. By integrating this company, SHL, a specialist for drug administration solutions, will be expanding its internal capacities for the production of plastic-based injection molds.

Zurich - Sevensense Robotics is now fully owned by ABB. Sevensense's autonomous mobile robots, capable of proprietary 3D image processing, complement ABB's solutions to create a working environment in the automotive and logistics industries by supporting people.

Zurich - In 2023, more start-ups were founded at the Swiss Federal Institute of Technology in Zurich (ETH) than ever before. Of the 43 spin-offs, 12 have clear links to artificial intelligence, while biotech and pharma spin-offs make up the biggest proportion of the total. The number of female founders is also increasing.

Manno - The University of Applied Sciences and Arts of Southern Switzerland (SUPSI) is using blockchain technology in connection with Ticino Alpine cheese: On the one hand, the Blockcheese project digitizes the registration of the cheese produced on the alpine pastures in the region, and on the other, offers consumers valuable insights into supply chains.

At Greater Zurich Area, we are committed to opening doors and forging connections between key players of our ecosystem and innovation-driven companies. In line with this mission, we've had the privilege of engaging with some of the most exciting personalities across our diverse ecosystems. Through a series of thought-provoking questions, we delve into their unique insights and experiences.

Schlieren/Plano/Paris - Molecular Partners and Orano Med are joining forces for the development of protein drugs known as DARPin therapeutics. The radioactive payloads of such drugs can destroy cancer cells. In this context, the therapeutics are said to minimize collateral kidney damage.